匹多莫德口服液辅助治疗传染性单核细胞增多症的疗效分析

目的 观察匹多莫德口服液辅助治疗传染性单核细胞增多症的疗效及对T淋巴细胞亚群的影响。方法 选取2016年7月至2017年6月收治的传染性单核细胞增多症患儿共76例为研究对象，随机分为常规治疗组和匹多莫德组各38例，常规治疗组给予注射用更昔洛韦抗病毒及常规对症治疗，匹多莫德组在此基础上加用匹多莫德口服液，疗程2周。分别比较两组临床指标的恢复情况及外周血T淋巴细胞亚群的变化。结果 匹多莫德组患儿热退时间、扁桃体炎消退时间、肿大淋巴结缩小时间、肿大肝脾缩小时间及住院时间均较常规治疗组显著缩短（P < 0.05）。匹多莫德组治疗后CD3⁺、CD8⁺水平较治疗前及常规治疗组治疗后下降（P < 0.001）；CD4⁺水平、CD4⁺/CD8⁺比值较治疗前及对照组治疗后上升（P < 0.001）。对照组在治疗2周后T淋巴细胞亚群较治疗前无明显变化（P > 0.05）。结论 匹多莫德口服液辅助治疗传染性单核细胞增多症有良好的临床疗效，并能改善细胞免疫功能，值得临床推广应用。

Clinical effect of pidotimod oral liquid as adjuvant therapy for infectious mononucleosis

Objective To study the clinical effect of pidotimod oral liquid as adjuvant therapy for infectious mononucleosis and its effect on T lymphocyte subsets.Methods A total of 76 children with infectious mononucleosis, who were admitted to the hospital between July 2016 and June 2017, were enrolled and randomly divided into two groups:conventional treatment and pidotimod treatment (n=38 each). The children in the conventional treatment group were given antiviral therapy with ganciclovir for injection and symptomatic treatment. Those in the pidotimod treatment group were given pidotimod oral liquid in addition to the treatment in the conventional treatment group. The course of treatment was two weeks for both groups. The two groups were compared in terms of the recovery of clinical indices and the changes in peripheral blood T lymphocyte subsets.Results Compared with the conventional treatment group, the pidotimod treatment group had signifcantly shorter fever clearance time, time to the disappearance of isthmopyra, time to the relief of lymph node enlargement, time to the relief of hepatosplenomegaly, and length of hospital stay (P < 0.05). After treatment, the pidotimod treatment group had signifcant reductions in the percentages of CD3⁺ and CD8⁺ T cells and had signifcantly lower percentages of CD3⁺ and CD8⁺ T cells than the conventional treatment group (P < 0.001). The pidotimod treatment group had signifcant increases in the percentage of CD4⁺ T cells and CD4⁺/CD8⁺ ratio after treatment, which was signifcantly higher than those in the conventional treatment group (P < 0.001). The conventional treatment group had no signifcant changes in T lymphocyte subsets after treatment (P > 0.05).Conclusions Pidotimod oral liquid has a good clinical effect as the adjuvant therapy for infectious mononucleosis and can improve cellular immune function, so it holds promise for clinical application.